Gossamer Bio Is Maintained at Buy by Chardan Capital

What happened

Chardan Capital maintained its Buy rating on Gossamer Bio and kept a $160.00 per share price target, according to Benzinga ratings actions reported at 12:18 GMT.

Confirmed

Global impact / market context

A maintained Buy rating and unchanged price target suggest the analyst still sees the shares as undervalued; for investors, it signals continued confidence even though no new estimate or thesis was disclosed.

Analyst inference

This is a single analyst action on Gossamer Bio, a biotech stock. Ratings and price targets can shape investor positioning, but one unchanged call gives limited new information on its own.

Analyst inference

What to watch

1. Watch whether Chardan Capital later changes its Buy rating or its $160.00 per share price target, since either move would alter the meaning of this call. Confirmed
2. Track any new company updates Gossamer Bio may publish, as such disclosures could lead analysts to revisit ratings and targets. Proposed
3. Compare other analysts' ratings and targets on Gossamer Bio to judge whether Chardan's view stands apart from the wider analyst consensus. Analyst inference

Evidence

• Original source link unavailable